drugset / Trial / NCT05335993
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
Phase 2
Active not recruiting
10 enrolled
CanariaBio Inc.
Raptim Research · collabVeristat, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.
Timeline
- Start
- 2022-07-25
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 200 mg | Oral |
| Subject | Niraparib | Small molecule | 300 mg | Oral |
| Subject | Oregovomab | Monoclonal antibody | 2 mg | Intravenous |